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Attention deficit hyperactivity disorder
(ADHD) is the most common psychiatric dis-
order in children and adolescents, with
6–12% being affected worldwide according to
the Diagnostic and Statistical Manual of
Mental Disorders, 4th text revision (DSM-IV-
TR 2000; see also Biederman and Faraone
2005). Methylphenidate (MPH), a central
nervous system stimulant, is the most fre-
quently prescribed drug for the symptomatic
treatment of ADHD and has consistently
shown efficacy and safety. Although MPH
was introduced about 50 years ago, no conclu-
sive data are currently available to assess the
long-term beneﬁts and risks. A recent report
(El-Zein et al. 2005) on cytogenetic effects
observed in peripheral lymphocytes (PBL)
from 12 ADHD children treated for 3
months with MPH raised questions about the
genetic toxicity of this drug. On average, 3.0-,
4.3-, and 2.4-fold increases were found in
chromosome aberrations (12 cases), sister
chromatid exchanges (11 cases), and micronu-
clei frequencies (11 cases), respectively. The
authors (El-Zein et al. 2005) cautioned that
“the data should be replicated and expanded”
but also stated that “the lack of research on
long-term effects of methylphenidate use in
humans warrants great concern.” This great
concern arose because cohort studies have
shown an association between the frequency of
cells with structural chromosomal aberrations
or micronuclei in peripheral blood lymphocytes
and cancer risk (Bonassi et al. 2004, 2006;
Hagmar et al. 2004). Considering the
extremely high current estimated prescription
rate of MPH of over 5 million per year in the
United States (Physician Drug and Diagnosis
Audit 2003), a thorough investigation of the
safety of this important medication for chil-
dren with ADHD is essential. 
Using a standard genotoxicity test battery,
Teo et al. (2003) evaluated the activity of
MPH in the bacterial reverse mutation assay
and mouse lymphoma mammalian mutation
assay with and without metabolic activation,
and in a bone marrow micronucleus test in
male and female CD-1 mice. Although sub-
stance-associated toxicity was observed in the
mammalian tests, no mutagenic or clastogenic
effects were induced. This was recently further
supported by negative genotoxicity ﬁndings in
the in vitro human lymphocyte chromosomal
aberration assay and the mouse bone marrow
micronucleus test (Suter et al. 2006).
Epidemiologic data are limited to one
report of a cohort study of 143,574 patients;
the researchers screened MPH, among other
prescription drugs, for possible carcinogenic-
ity and found no increase in cancer (Selby
et al. 1989). However, the small sample size
of 529 MPH-treated patients (15 cancer cases
instead of 32.7 expected cases) and the short
observation period of up to 15 years limit the
interpretation. According to recent overviews
responding to the findings of elevated
genomic damage in children (Holtmann et al.
2006; Preston et al. 2005), MPH was not
found to be carcinogenic in a long-term rat
bioassay, but yielded an increase in hepatic
neoplasms in B6C3F1 mice at the highest test
dose of 56–66 mg/kg body weight/day,
which is about 60-fold above the recom-
mended doses for ADHD patients (Taylor
et al. 2004). Because of these hepatic neo-
plasms, MPH was judged by the National
Toxicology Program (NTP) of the National
Institute of Environmental Health Sciences to
yield “some evidence of carcinogenic activity”
(NTP 1995).
The aim of this study is to provide new
data on the potential mutagenicity of MPH
in children. We assessed the cytogenetic
effects of MPH treatment by evaluating the
frequency of micronuclei, a subgroup of chro-
mosomal aberrations, in ADHD children.
We present data on the results before and
1 month (30 children), 3 months (21 chil-
dren), and 6 months (8 children) after initia-
tion of MPH treatment. Additionally, we
analyzed 9 patients who had been medicated
with MPH between 6 and 24 months.
Methods
Participants. The study was approved by the
ethics committee of the University of
Würzburg (study no. 140/03), and written
informed parental consent was obtained for
all patients before participation in the study. 
Children with ADHD and no previous
medication were recruited between May
2005 and April 2006. The patients were
characterized by a team of consultant child
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BACKGROUND AND OBJECTIVE: Attention deﬁcit hyperactivity disorder (ADHD) is the most common
psychiatric disorder in children and adolescents (6–12% affected). Treatment with methylphenidate
(MPH) in the United States has increased to a current prescription rate of > 5 million per year.
However, a 2005 study by El-Zein and co-workers [Cancer Lett 230:284–291] reporting a 3-fold
increase in genomic damage in all 12 analyzed children after 3 months of therapy with MPH
resulted in much concern about potential carcinogenic effects. Here we provide new information
concerning the cytogenetic effect of MPH in children. 
DESIGN, PARTICIPANTS, AND METHODS: In a prospective study, we analyzed the genomic damage in
children with ADHD (initial sample size 38 children) before and 1 (30 children), 3 (21 children),
and 6 (8 children) months after initiation of MPH therapy. In addition, we investigated a group of
9 children receiving chronic MPH therapy. Patients were recruited within a study of our Clinical
Research Group on ADHD in the Department of Child and Adolescent Psychiatry and
Psychotherapy of the University of Würzburg. Assessment and treatment of patients were per-
formed during inpatient or outpatient health care. The measure for genomic damage was the fre-
quency of micronuclei, a subset of chromosomal aberrations, in peripheral lymphocytes. 
RESULTS: MPH treatment resulted in no signiﬁcant alteration in the micronucleus frequency. 
CONCLUSIONS: Because the findings published in 2005 by El-Zein and co-workers could not be
replicated, the concern regarding a potential increase in the risk of developing cancer later in life
after long-term MPH treatment is not supported. 
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21 February 2007]and adolescent psychiatrists at the Department
of Child and Adolescent Psychiatry and
Psychotherapy of the University of Würzburg.
The patients were assessed and treated during
inpatient or outpatient health care; semistruc-
tured interview and the Schedule for Affective
Disorders and Schizophrenia for School-Aged
Children (K-SADS) (Kaufman et al. 1997)
were used as diagnostic inventories. The
recruitment was done within a study of our
Clinical Research Group on ADHD with the
objective of family-based association and
genome-wide linkage studies. 
Exclusion criteria were current smoking,
current infection or an infection in the 14
days before blood sampling, or extreme food
patterns (e.g., vegans) of the children.
Psychiatric diagnoses such as anorexia ner-
vosa, schizophrenia, any pervasive develop-
mental disorders, neurologic disorders such as
epilepsy, a history of any acquired brain dam-
age, or evidence of a fetal alcohol syndrome,
premature deliveries and/or maternal reports
of severe prenatal, perinatal, or postnatal
complications, as well as severe diseases were
also regarded as exclusion criteria.
We investigated an additional sample
consisting of nine children, who had been
medicated with MPH for more than
6 months (chronic treatment). Four of them
had received comedications (three risperidone
and one valproic acid) before the beginning of
the study. Except for the medication, the
same recruitment and exclusion criteria were
applied. The MPH treatment (organized by
sex) for the prospective study and the chronic
treatment group is given in the tables. 
Group description and missing data of the
prospective investigation. All children fulﬁlled
the diagnostic criteria for ADHD according to
DSM-IV-TR (2000) and were completely
drug naive before being enrolled in the study.
Of the 38 patients who were identified as
potential participants, 8 patients (group A)
were not medicated with MPH or did not
want to participate further in the study. Two
patients withdrew because of nonresponse to
MPH and change of treatment to ampheta-
mine and atomoxetine, respectively, and 7
patients were lost at follow-up. These circum-
stances both occurred after the 1-month visit.
Therefore, 9 patients (group B) could be
placed in the 1-month follow-up, 13 patients
(group C) could be included in the 1- and
3-month follow-up, and 8 more patients were
analyzed after 1, 3, and 6 months (group D).
Thus the groups A, B, C, and D represent
patients from whom we could collect one,
two, three, and four blood samples, respec-
tively, during the course of the study (Tables 1
and 2).
Collection of blood samples. Blood samples
(7.5 mL each) were collected 1 day before, and
1, 3, and 6 months after MPH treatment for
micronucleus analysis. From each participant
of the chronic treatment group, one blood
sample was analyzed. Blood samples were
taken via an in-dwelling cannula and collected
in coded tubes containing heparin. When
blood samples were collected before 1700 hr,
the samples were transported at room tempera-
ture to the nearby Department of Toxicology,
University of Würzburg, for immediate isola-
tion of peripheral blood mononuclear cells
(PBMCs); when samples were taken after
1700 hr, they were stored at room tempera-
ture pending isolation of PBMC the following
morning.
Cell isolation. PBMCs were isolated by
standard density gradient centrifugation using
FicoLite H (Linaris-H, Wertheim, Germany).
In brief, the blood was layered (1:1) onto
FicoLite H (Linaris) and centrifuged at 1,600
rpm (370 × g) for 30 min at room tempera-
ture. The PBMC layer was removed and the
cells were washed twice (1,300 rpm; 250 × g;
10 min) with RPMI-1640 (Sigma-Aldrich
Chemie GmbH, Steinheim, Germany). 
Culture conditions. PBMCs were cul-
tured at a cell density of 1 Mio (millions)/mL
in 5 mL of culture medium at 37°C in a
humiﬁed, 5% carbon dioxide incubator. The
culture medium consisted of RPMI-1640,
supplemented with 15% fetal bovine serum,
2 mM L-glutamine, 1 mM Na-pyruvate,
nonessential amino acids, and antibiotics
(penicillin/streptomycin/tylosin). To stimu-
late the lymphocytes for proliferation, PHA
(phytohemagglutinine; final concentration
10 µg/mL) was added. 
Micronucleus assay. The micronucleus
scoring was carried out by a single scorer six
times for each sample in a blinded manner.
Because DNA damage can be expressed as
micronuclei only after going through mitosis,
the analysis was limited to actively dividing
lymphocytes. These were identiﬁed as binucle-
ated cells on addition of the cytokinesis-
inhibitor cytochalasin B (final concentration
5 µg/mL). Cytochalasin B was added to the
cultures 44 hr after stimulation with PHA. At
72 hr after culture initiation, the cells were
spun on glass slides with a cytocentrifuge
(Cytospin 3; Shandon/Thermo, Dreieich,
Germany; 1,000 rpm; 145 × g, 5 min).
Subsequently, fixation in cold (–20°C)
methanol was performed for at least 2 hr.
Slides were stored at –20°C in sealed boxes.
Before evaluation, slides were stained with
acridine orange (0.00625% in Sorensen
buffer, w/v, pH 6.8) for 5 min, and washed
twice in Sorensen buffer [67 mM Na2HPO4/
KH2PO4 (pH 6.8)]. Sample preparation (cell
culture, slide preparation) was limited to two
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Table 1. Individual dosage of MPH analyzed after 1, 3, and 6 months for all children of groups B, C, and D. 
Dosage of MPH (mg/day)









F 18 long-acting, 5 short-acting
M1 0
Group C
M2 0 3 0
F1 0 2 0
M 30 long-acting 40 long-acting
M 40 long-acting 40 long-acting
M 18 long-acting 36 long-acting
M2 0 3 0
M1 5 2 0
M1 5 1 5
F2 0 3 0
F1 0 2 0
M1 5 4 0
M5 2 0
M1 8 1 8
Group D
F 15 20 25 long-acting
M2 0 2 0 3 0
M2 0 2 0 3 0
M1 0 1 5 1 5
F 36 long-acting 36 long-acting 54 long-acting
M2 0 2 0 2 0
F1 5 2 0 2 0
M 20 25 20 long-acting
Abbreviations: F, female; M, male. Unless otherwise noted, the short-acting pharmaceutical preparation has been given.laboratory members, staining of slides to one.
From each blood sample, 6,000 binucleated
lympocytes (6 slides, 1,000 cells per slide)
were screened for the presence of micronuclei
with ﬂuorescence microscopy at 400× magni-
ﬁcation. The scoring criteria corresponded to
those described by Fenech et al. (2003). 
In addition, from 6,000 cells of each
sample, we determined the cytokinesis block
proliferation index (CBPI) [(number of
mononucleate cells + 2× number of binucle-
ate cells + 3× number of multinucleate cells)/
(sum of mononucleate, binucleate, and multi-
nucleate cells)]. 
Statistics. Data are shown as mean ± SD
of micronucleated cells per 1,000 binucleated
cells. Microsoft Excel was used to organize
data. WinStat (demo version; R. Fitch
Software, Bad Krozingen, Germany; Statistics
for Excel, Microsoft Corporation, Redmond,
WA, USA) was applied for calculation of
correlations (Pearson). Because data were not
strictly normally distributed (as analyzed by
WinStat) we applied both the paired t-test
and Wilcoxon test for comparison of each
sampling time with values before initiation of
therapy. An overall analysis and an analysis of
the most informative subgroup across three
sampling times (before, 1 month, 3 months)
were performed with Kruskal-Wallis.
Independent groups were compared with the
two-sample t-test and the two-sample
Wilcoxon test. A p-value of ≤ 0.05 was con-
sidered signiﬁcant. 
Results
The mean (± SD) age of the children in the
initial study group (n = 38; groups A–D,
Tables 1, 2; Figure 1) was 10.0 ± 2.8 years
(range, 4.9–17.0 years). The sample included
29 male and 9 female children (all of German
origin). The mean age of the 21 patients from
whom at least three blood samples were
collected (groups C + D; Tables 1, 2; Figure 1),
was 9.7 ± 2.8 years (range, 4.9–17.0 years).
The average of children’s body weight was
34.5 ± 13.5 kg (range, 23.6–82.0 kg). During
the ﬁrst month, the children were medicated
with an individual dose of MPH, ranging
from 5 to 40 mg/day, equivalent to a mean of
0.54 mg/body weight/day, and during the
subsequent 3 months with a dose of MPH
ranging from 15 to 45 mg/body weight/day,
equivalent to 0.74 mg/body weight/day. Sex,
individual MPH doses, and pharmaceutical
preparation (short-acting, long-acting) are
given in Table 1. Comparable to our investi-
gation, in the study of El-Zein et al. (2005)
the patients received therapeutic dosages rang-
ing from 20 to 54 mg/day after 3 months. 
In our chronic treatment group (Table 3),
consisting of nine boys with long-term medica-
tion of MPH (6 months to 2 years) the mean
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Table 2. Individual frequencies of micronucleated lymphocytes of children with ADHD before and after MPH treatment at three follow-up intervals. 
Before treatment  After 1 month  After 3 months  After 6 months
Group (no. of subjects) Mn-Cells CBPI Mn-Cells CBPI Mn-Cells CBPI Mn-Cells CBPI
A (8) 10.00 ± 2.00 1.73
8.00 ± 4.73 1.73
5.83 ± 0.75 1.70
5.00 ± 0.89 1.69
4.00 ± 2.97 1.75
4.00 ± 2.00 1.73
3.67 ± 0.82 1.69
2.00 ± 0.89 1.88
B (9) 17.00 ± 4.69 1.82 4.00 ± 1.79 1.79
7.83 ± 4.12 1.70 15.00 ± 6.13 1.74
7.00 ± 1.55 1.74 3.00 ± 0.89 1.85
6.00 ± 3.58 1.92 2.50 ± 0.84 1.56
5.67 ± 1.21 1.63 4.67 ± 1.03 1.63
5.33 ± 2.07 1.78 2.17 ± 1.33 1.69
4.00 ± 1.29 1.77 2.67 ± 0.82 1.78
3.00 ± 0.89 1.58 5.33 ± 1.03 1.67
2.67 ± 0.82 1.77 3.67 ± 0.82 1.68
C (13) 16.00 ± 4.34 1.88 14.00 ± 2.37 1.81 5.00 ± 1.78 1.75
11.67 ± 4.08 1.70 6.67 ± 1.63 1.68 5.50 ± 1.38 1.66
8.83 ± 2.32 1.76 13.00 ± 2.53 1.74 7.33 ± 2.50 1.76
8.00 ± 0.89 1.69 8.17 ± 3.60 1.74 6.00 ± 1.67 1.70
7.00 ± 2.19 1.67 4.00 ± 3.03 1.75 8.00 ± 1.79 1.84
7.00 ± 1.41 1.79 3.00 ± 2.53 1.72 5.17 ± 2.32 1.82
6.00 ± 1.27 1.77 10.00 ± 2.83 1.85 1.67 ± 1.03 1.72
4.83 ± 2.14 1.75 7.83 ± 2.32 1.80 5.00 ± 2.10 1.78
4.00 ± 1.27 1.76 6.67 ± 1.03 1.85 3.67 ± 1.21 1.92
4.00 ± 2.00 1.73 4.33 ± 1.21 1.66 5.33 ± 1.37 1.66
3.00 ± 3.03 1.74 3.00 ± 1.55 1.73 3.67 ± 1.63 1.69
2.83 ± 2.14 1.75 3.00 ± 1.27 1.84 7.67 ± 2.94 1.73
2.00 ± 0.89 1.80 2.83 ± 1.47 1.85 9.67 ± 4.41 1.81
D (8) 21.00 ± 5.22 1.76 10.00 ± 5.37 1.74 13.67 ± 3.50 1.85 5.00 ± 0.89 1.71
6.17 ± 1.17 1.81 5.33 ± 1.03 1.81 6.50 ± 1.38 1.84 5.67 ± 0.82 1.78
4.17 ± 1.47 1.73 2.00 ± 2.28 1.77 11.50 ± 4.85 1.77 3.50 ± 1.64 1.80
3.17 ± 2.86 1.65 3.00 ± 1.41 1.74 1.50 ± 1.05 1.67 3.33 ± 0.52 1.67
3.00 ± 1.79 1.78 16.00 ± 2.19 1.85 2.00 ± 1.41 1.72 5.67 ± 1.37 1.79
2.67 ± 1.75 1.74 3.00 ± 1.27 1.72 4.83 ± 2.48 1.78 5.17 ± 1.17 1.74
2.00 ± 0.63 1.80 8.17 ± 3.76 1.78 5.50 ± 2.34 1.68 4.33 ± 1.03 1.64
2.00 ± 0.63 1.69 2.00 ± 1.27 1.70 27.83 ± 3.71 1.78 3.67 ± 0.82 1.70
Total no. of patients 38 38 30 30 21 21 8 8
Mean ± SD 6.06 ± 4.29 1.75 ± 0.07 5.97 ± 4.12 1.76 ± 0.08 7.00 ± 5.65 1.76 ± 0.07 4.54 ± 0.96 1.73 ± 0.06
p-Value (t-test/Wilcoxon) 0.75/0.75 0.53/0.41 0.60/0.96 0.61/0.78 0.67/0.55 0.54/0.81
Values for micronucleated lymphocytes (Mn-Cells) are mean ± SD from 6 analyses of 1,000 binucleated lymphocytes. The cytokinesis block proliferation index (CBPI) from 6,000 cells
is indicated for each time point. Significance was analyzed using the paired t-test and the Wilcoxon test to compare data from each time point with the same individuals before
therapy initiation. age was 11.2 ± 2.8 years (range, 7.1–16.0
years). All of them had been medicated with a
dose ranging from 15 to 60 mg/day. The aver-
age body weight was 45.5 ± 16.2 kg (range,
22.8–77.1 kg), and the average dose of MPH
was equivalent to a mean of 0.83 mg/body
weight/day. Three of these patients had addi-
tionally received risperidone (range, 0.5–1.5
mg/day) and one of them valproic acid (1,500
mg/day) for longer than 6 months.
From the prospective study, 38 pretreat-
ment blood samples were available for
micronucleus analysis in binucleated lympho-
cytes (groups A–D; Table 2, Figure 1). In
untreated children we determined 6.1 ±
4.3/1,000 binucleated cells. There was no
correlation between basal micronucleus num-
bers and sample admission date (r = –0.22;
p = 0.10), suggesting no seasonal influences
on micronucleus numbers. Within this age
group, donor age did not correlate with
micronucleus frequency (r = 0.02; p = 0.45).
Because of limited sample size (nine female
patients), we performed no analysis for inﬂu-
ence of sex. 
Figure 1 and Table 2 give the number of
micronucleated cells before and after MPH
treatment at three different follow-up time
points. The micronucleated cell frequencies at
each follow-up compared with the baseline
value did not demonstrate any significant
increase (paired t-test and Wilcoxon test).
Analysis of all groups with Kruskal-Wallis
yielded no signiﬁcant alterations. Table 2 also
indicates that there was no significant alter-
ation (t-test and Wilcoxon test) in the cell
proliferation capability in response to phyto-
hemagglutinine stimulation in vitro (CBPI)
after initiation of MPH therapy. 
In addition, we gathered samples (one
time point) from children who had received
MPH for at least 6 months (6 months–2 years
of chronic treatment). This group of nine chil-
dren (Table 2) did not show a significantly
different (p = 0.49/0.69; t-test/Wilcoxon; two
sample tests performed separately) mean
micronucleated lymphocyte frequency com-
pared with the pre-treatment mean of our
study group. 
In addition to the assessment of micronu-
cleus numbers, we measured safety by analyz-
ing changes in vital signs, electrocardiograms,
and clinical laboratory values such as white
and red blood count, electrolytes, and
transaminases according to the recommenda-
tions for MPH therapy (Warnke and Walitza
2004). No abnormal parameters were
observed except slightly reduced values of total
iron, without signs of hypochromic microcytic
anemia, which occurred in some patients
before and during the treatment, independent
of micronucleus deviation. We could not
detect reasons for increased micronucleus fre-
quencies of individual children at isolated time
points such as pathologic laboratory parame-
ters, eating behavior, weight, or dose per
weight. We reconsulted all patients with
micronucleus frequencies of ≥ 10/1,000 binu-
cleated cells to ascertain whether they had
been exposed to radiation, such as medical
X-ray exposure or cosmic radiation within the
preceding 2 years. Because only one patient
reported one flight 2 years before the study,
one patient had been hiking higher than
3,000 m, and another patient had one maxilla
X ray for getting a brace, radiation exposure
does not explain these isolated elevated
micronucleus frequencies at single time points.
Discussion 
In this study we did not ﬁnd any alteration in
the number of micronucleated cells after
MPH treatment at three follow-up intervals
(up to 6 months). These results suggest no
induction of genomic damage and are in con-
trast to a recent report by El-Zein et al. (2005)
showing elevated genomic damage 3 months
after initiation of MPH therapy using three
cellular genotoxicity end points—frequency of
micronucleus formation, chromosomal aberra-
tions, and sister-chromatid exchanges (SCE).
A micronucleus is formed during cell divi-
sion, expressing previously induced chromo-
somal damage, and contains chromosomal
fragments and—less frequently—whole chro-
matids or chromosomes. SCE analysis detects
exchanges between sister chromatids harbor-
ing identical genetic information, thus not
directly representing a mutagenic effect.
Although chromosomal aberration studies are
very common in human genetic analysis and
cancer research, micronuclei are the cytoge-
netic end point most often used for current
human exposure biomonitoring studies. For
example, HUMN (Human MicroNucleus;
http://ehs.sph.berkeley.edu/holland/humn/)
is an international collaborative project of
> 40 laboratories from all over the world doc-
umenting micronucleus frequencies in human
populations. HUMN is currently focusing on
human lymphocytes and exfoliated epithelial
cells as biomonitors for exposure to toxic sub-
stances, and as potential predictors of adverse
health effects (Fenech et al. 1999). Recently,
Bonassi et al. (2006) found that an increased
micronucleus frequency in peripheral blood
lymphocytes predicts the risk of cancer in
humans. 
El-Zein et al. (2005) reported an average
micronucleus frequency of 3.55 ± 0.68/1,000
binucleated cells in drug-naive patients,
whereas we found 6.1 ± 4.3 micronucleated
cells/1,000 in this study. As with El-Zein
et al., some researchers prefer to score the
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Table 3. Individual frequencies of micronucleated lymphocytes of children with ADHD who had received
chronic MPH treatment for at least 6 months. 
Treatment duration (months) Sex Dosage of MPH (mg/day) Mn-Cells CBPI
13 Ma 60 3.67 ± 0.82 1.70
6M b 35 4.00  ± 0.89 1.67
8 M 45 5.83 ± 1.47 1.73
24 Mc 25 2.00 ± 1.79 1.63
15 M 54 long-acting 5.33 ± 1.21 1.60
11 M 25 7.67 ± 0.82 1.67
6 M 40 1.83 ± 1.33 1.62
12 Md 40 8.83 ± 1.47 1.79
24 M 15 6.00 ± 0.89 1.75
Total no. of patients 9 9
Mean ± SD 5.02 ± 2.38 1.69 ± 0.06
M, male. Values for micronucleated lymphocytes (Mn-Cells) are mean ± SD from 6 analyses of 1,000 binucleated lympho-
cytes. The cytokinesis block proliferation index (CBPI) from 6,000 cells is indicated. 
aRisperidone: 0.5 mg/day. bRisperidone: 1 mg/day. cRisperidone: 1.5 mg/day. dValproic acid: 1,500 mg/day.
Figure 1. Individual frequencies of micronucleated peripheral lymphocytes of children with ADHD before
and after MPH treatment at three follow-up intervals. BNC, binucleated cells. In group A, all children were
included for whom only a basal value (before start of medication) was obtained. The groups B, C, and D
included patients for whom values after 1 month (follow-up 1), 3 months (follow-up 2), and 6 months (fol-
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number of micronuclei per 1,000 cells rather
than the number of micronucleated cells, as
recommended for genotoxicity testing in the
Organisation for Economic Co-operation and
Development (OECD) guideline draft
(OECD 2006). Because cells with more than
one micronucleus are rare, the difference
between these variants is small, and the num-
ber of micronuclei would be higher than the
number of micronucleated cells. In a meta-
analysis aimed at providing reference values
for basal micronucleus frequencies (no expo-
sure to genotoxic agents, no disease), data
from 13 publications with micronucleus data
of children (440 children 0–19 years of age)
gives an overall mean of 4.48 ± 0.66 micronu-
clei/1,000 binucleated cells (Neri et al. 2005).
Based on the data collection from 12 labora-
tories for a pooled analysis of individual data
(332 referents, 0–18 years of age; data from
HUMN database) an overall mean ± SE of
5.23 ± 5.07 micronuclei/1,000 binucleated
cells was calculated (Neri et al. 2005).
Speciﬁcally, the age groups of 5–9 and 10–14
years had pooled estimated means of 5.62 and
6.02, respectively. Thus, our data (mean age,
10.0 years) are in excellent agreement with
the published literature. 
Searching for possible explanations for the
difference between our study and that of
El-Zein et al. (2005), we are not aware of varia-
tions between the methods and procedures; El-
Zein et al. (2005) did not describe methods in
detail because of space limitations, so they
denoted them as “standard procedures” in a
later comment (El-Zein et al. 2006). In that
comment, they excluded changes in the
patients’ health, environment, diet, or lifestyle
as reasons for the observed elevation in the level
of cytogenetic damage. Seasonal influences
could be excluded in our database; it is not
known whether this was also possible in their
study. Differences concerning doses of MPH or
type of pharmaceutical preparation, potentially
increasing the contact time between MPH and
peripheral lymphocytes, are not apparent
between both studies, but El-Zein et al. (2005)
do not describe individual dosage and pharma-
ceutical preparation of the medication.
Although there is no evidence of cyto-
chrome P450 (CYP450)-dependent reactions
in the metabolism of MPH in humans,
Le Nedelec and Rosengren (2002) have found
that MPH decreased total hepatic CYP450 in
the mouse and altered the catalytic activity
and/or the polypeptide levels of CYP1A,
CYP2E1, and CYP3A. Thus, CYP450 poly-
morphisms may inﬂuence the effects of MPH.
Because polymorphisms are not distributed
equally among populations worldwide, we can-
not exclude different extends of polymor-
phisms between the El-Zein study (2005) and
ours. This presumption is supported by the
fact that the investigated group of El-Zein et al.
consisted of patients with different ethnicities
(six Caucasians, four African Americans, and
two Hispanic children), whereas our sample
includes only patients of German origin.
Based on our results, concern about a
potential increase in the cancer risk later in
life after long-term MPH treatment needs to
be reconsidered. This is also supported by the
fact that our “chronic treatment” group did
not show a significant difference in micro-
nucleated cells compared with the pretreat-
ment values of the study group. Nonetheless,
the widespread use of MPH still suggests a
need for further research on this important
topic, including extension of this study to
examine potential long-term effects. 
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